Vaccines are biological in nature. It's very possible that time will be a much more meaningful factor than people or equipment in producing enough of a vaccine to cover sufficiently many people so "massively parallelizing" the process may not help with the lead time to vaccine availability, only with quantity when it does become available (assuming an effective vaccine is found).
Having said that, I would expect that in most Western countries, sufficient quantities to cover the most vulnerable people (older people and those with existing heart or respiratory conditions - ie largely the same people selected for annual flu vaccines in many places) will be available by next (Northern hemisphere) winter.
Having said that, I would expect that in most Western countries, sufficient quantities to cover the most vulnerable people (older people and those with existing heart or respiratory conditions - ie largely the same people selected for annual flu vaccines in many places) will be available by next (Northern hemisphere) winter.
reply